Eli Lilly Raises 2026 Revenue Outlook to $85B-$87B After Strong Q2 Earnings
Macro·1 article across 1 outlet
Story updated Rewritten when the story materially grows; the wire is checked every 15 minutesAbout this data
Eli Lilly reported strong quarterly earnings, easily surpassing estimates, driven by surging sales of Zepbound and Mounjaro. The company now expects 2026 revenue to come in between $85 billion and $87 billion, up from previous guidance of $82 billion to $85 billion.
This positive performance reflects the growing demand for its products, indicating a robust market position for Eli Lilly as it continues to innovate and expand its offerings.
Eli Lilly
Sources
Every quote below is verbatim from the article it is attributed to.
SourceReports the news
“Eli Lilly now expects 2026 revenue to come in between $85 billion and $87 billion, up from previous guidance of $82 billion to $85 billion.”
CNBC — Eli Lilly easily tops quarterly estimates, raises outlook as Zepbound and Mounjaro sales surge